Publication Month: Sep 2021 | Report Code: TIPRE00006184 | No. of Pages: 259 | Category: Biotechnology | Status: Published
Immunohistochemistry (IHC) uses microscopy-based techniques to observe cellular components such as proteins or other macromolecules in a tissue sample. It is a routinely used tool in health care and pathology. IHC is widely used in research applications where molecules of interest are analyzed to study their roles in both healthy and diseased cells and tissues on the cellular, molecular, or tissue level. Numerous IHC methods can be used to localize antigens. Parameters like specimen types and assay sensitivity are majorly considered in IHC.
The immunohistochemistry market is segmented into product, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with the analysis of the competitive landscape of the globally leading market players.
Immunohistochemistry (IHC) refers to an important application of monoclonal and polyclonal antibodies for tissue determination and distribution of antigens of a particular disease. It is majorly used to detect several infectious disorders such as dengue, hepatitis, and AIDS. Immunohistochemistry helps diagnose chronic medical conditions such as obesity, cancer, diabetes, heart disease, and stroke.
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 37.6 million people across the globe had HIV in 2020. 35.9 million were adults, and 1.7 million were children (<15 years old). An estimated 1.5 million individuals worldwide acquired HIV in 2020. According to the HIV and AIDS organization (AVERT), in 2018, 1.1 million US residents were infected with HIV, whereas APAC registered 5.2 million HIV-infected population. According to the European CDC, ~2 million people in Europe were infected with HIV in 2018.
Diabetes is prevailing at a high rate in the geriatric population worldwide. The prevalence of diabetes is more in overweight and obese people. As per data published by the Centers for Disease Control and Prevention (CDC) in 2017, ~30.3 million people, representing 94% of the population of the US, were diabetic. Among these, ~23.1 million people were diagnosed with diabetes, while ~7.2 million had not undergone a proper diagnostic procedure.
The obesity rates have been increasing rapidly in developed as well as developing economies across the globe. Factors such as unhealthy lifestyles and sedentary life are significant factors for the rise in the number of obese individuals. As per the data published by National Center for Health Statistics (NCHS), the prevalence of obesity is expected to be around 39.8%, affecting about 93.3 million US adults between the years 2015 to 2016. The incidence of obesity was significantly high among middle-aged adults (42.7%) compared to younger adults (35.7%). The increase in the number of obese people in the US has also led to rising healthcare expenditure.
Cardiovascular diseases (CVDs) include cerebrovascular disease, rheumatic heart disease, coronary heart disease, and other conditions. It is the most significant cause of morbidity and mortality worldwide. According to the European Cardiovascular Disease Statistics 2017, every year, cardiovascular diseases cause 3.9 million deaths and more than 1.8 million deaths in the European Union (EU). CVDs account for 45.0% of all deaths in Europe and 37.0% of deaths in the EU. Furthermore, as per the American Heart Association (AHA) 2019 statistics, 121.5 million adults in the US—which is around half of the US adult population—suffer from cardiovascular diseases.
Furthermore, there has been a rise in cancer incidence and mortality rates worldwide, making cancer the leading cause of death. According to the World Health Organization (WHO), in 2018, cancer was the cause of approximately 9.6 million deaths worldwide.
Moreover, according to the National Cancer Institute, in 2018, approximately 1,735,350 new cancer cases were diagnosed in the US. Similarly, in China, as per the data revealed by WHO, ~4.3 million new cancer cases were detected, and 2.9 million cancer deaths were recorded in 2018. Such an increase in the incidence of chronic and infectious diseases is expected to create a demand for immunoassay tests worldwide.
The increasing prevalence of chronic diseases can be majorly attributed to the growing elderly population. Aging is a complex process influenced by genetic variables, as well as environmental factors. Thus, people in the age group of 75 years and above, suffering from high blood pressure, are the common risk factor for cardiovascular diseases, including blood-associated cancer. Management of these disorders in older patients must often be weighed in a setting of decreased physiological reserves and concurrent illnesses.
According to the United Nation's World Population Ageing 2017 report, in 2017, 962 million people across the world were aged 60 years or over. The number is expected to reach nearly 2.1 billion by 2050. In addition, according to the US Census Bureau, the number of Americans above the age of 65 and older is anticipated to grow more than double from 46 million in 2016 to above 98 million by 2060, and the 65-and-older age group's share in the world's population will increase to around 24% from 15%.
In 2017, Europe had the most significant percentage of the population of age group 60 or above (25%). According to the European Union (EU), the share of those aged 80 years or above is predicted to almost triple between 2011 and 2060. Rapid aging is occurring in other parts of the world as well. By 2050, all regions of the world, except Africa, will have nearly a quarter or more of their populations aging 60 and above. The number of older persons in the world is anticipated to be US$ 1.4 billion in 2030 and US$ 2.1 billion in 2050 and will rise above US$ 3.1 billion in 2100.
According to the National Council on Aging, approximately 80% of adults suffer from at least one chronic disease, whereas 77% of aged people suffer from two. These chronic diseases majorly comprise cancer, heart disease, diabetes, and stroke. Immunohistochemistry techniques help in the quantification and diagnosis of these diseases accurately and reliably. The rising geriatric population in the world is likely to boost the growth of the immunohistochemistry market during the forecast period.
Based on product, the global immunohistochemistry market is segmented into antibodies, equipment, reagents, and kits. In 2020, the antibodies segment held the largest share of the market. However, the reagents segment is expected to register the highest CAGR in the market during 2021–2028. In immunohistochemistry, antibodies provide extremely high identification precision at the protein level, with better sensitivity and localization at the cellular or even subcellular scale. In the immunohistochemistry market, companies such as Thermo Fisher Scientific, Inc. and Bio-Rad Laboratories, Inc. provide antibodies for better analysis of the assays, which is expected to drive the market during the forecast period.
Based on application, the immunohistochemistry market is segmented into diagnostics and drug testing. The diagnostics segment held a larger market share in 2021. Moreover, the same segment is expected to hold a significant market share in the immunohistochemistry market due to the increasing use of IHC to diagnose various chronic diseases such as cancer, autoimmune diseases, infectious diseases, and nephrological diseases. The increase in the detection and diagnosis of various medical conditions worldwide is expected to drive the segment's growth.
Based on end user, the immunohistochemistry market is segmented into hospital & diagnostic laboratories, research institutes, and others. The hospital & diagnostic laboratories segment held the largest market share in 2021, and it is expected to continue dominating the market by 2028. The hospital & diagnostic laboratories segment is expected to hold a significant market share in the immunohistochemistry market due to the segment is also expected to grow at the fastest rate during the coming years owing to the hospitals are among the essential parts of the healthcare system of any country. Technological advancements aid hospitals in diagnosing and treating various disorders such as cardio, neuro, HIV, Hepatitis, oncology, and others.Immunohistochemistry Market, by Product – 2021 and 2028
|Market Size Value in||US$ 2,171.61 million in 2021|
|Market Size Value by||US$ 3,585.31 million by 2028|
|Growth rate||CAGR of 7.4% from 2021-2028|
|No. of Pages||259|
|No. of Tables||191|
|No. of Charts & Figures||93|
|Historical data available||Yes|
|Segments covered||Application, Product, End User and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Product launches and mergers and acquisitions are highly adopted strategies by the players operating in the global immunohistochemistry market. A few of the recent key product developments are listed below:
In April 2020, Bio-Rad launched a blood-based immunoassay kit to detect COVID-19. It is a blood-based immunoassay kit to identify antibodies to the SARS-CoV-2, the virus that causes COVID-19.
In September 2020, Thermo Fisher and Humanigen agreed to scale up the manufacturing of monoclonal antibodies for COVID-19. This business deal is expected to help scale up the manufacturing of California biotech's lenlizumab, a clinical-stage candidate for cytokine storm that the company was testing in severe COVID-19 patients for a possible emergency use approval following this year.
Coronavirus immunohistochemistry antibodies are immunological methods used to identify members of the Coronaviridae family of RNA viruses that infect birds and mammals. Antibodies against antigens expressed by several coronavirus strains, including SARS-CoV-2, SARS-CoV, MERS, and other non-human pathogens like feline coronavirus. Common coronavirus antibody targets include nucleocapsid (N) and spike glycoprotein (S). These antibodies are intended for immunohistochemical applications. Immunohistochemistry analysis shows the detection of differential expression levels of SARS-CoV-2 Coronavirus Nucleocapsid and demonstrates antibody specificity. Several market players are launching immunoassay kits in the market. For instance, in April 2020, Bio-Rad launched a blood-based immunoassay kit to detect COVID-19. It is a blood-based immunoassay kit to identify antibodies to the SARS-CoV-2, the virus that causes Covid-19. Hence, the rising demand for immunoassay kits to detect COVID-19 is positively impacting the immunohistochemistry market growth.
The global immunohistochemistry market is segmented into product, application, end user, and geography. In terms of product, the market is segmented into antibodies, equipment, reagents, and kits. Based on application, the immunohistochemistry market is segmented into diagnostics and drug testing. Based on end user, the immunohistochemistry market is segmented into hospital & diagnostic laboratories, research institutes, and others. In terms of geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.
The List of Companies - Immunohistochemistry Market